AMENDMENT AGREEMENT to the DISTRIBUTION AGREEMENT dated April 3, 1998 by and between CENTOCOR, INC., CNA DEVELOPMENT, LLC (as licensee to Centocor, Inc.’s worldwide rights to Golimumab Product), and SCHERING-PLOUGH (IRELAND) COMPANY (as successor in...Distribution Agreement • December 21st, 2007 • Schering Plough Corp • Pharmaceutical preparations
This Amendment Agreement (hereinafter the “Amendment Agreement”), dated as of December 20, 2007 (the “Amendment Date”), is made by and between Centocor, Inc. a corporation organized under the laws of Pennsylvania with its principal office at 800 Ridgeview Drive, Horsham, Pennsylvania (“Centocor”), CNA Development, LLC, a limited liability company organized under the laws of Delaware (“CNA Development”, and collectively with Centocor, the “Centocor Parties”); and Schering-Plough (Ireland) Company, a corporation organized under the laws of Ireland, with offices at Rathdrum, County Wicklow, Ireland (“Schering-Plough”) (Schering-Plough and the Centocor Parties, each referred to from time to time herein as a “Party” and collectively as the “Parties”). To the extent set forth herein, this Amendment Agreement modifies and amends the Distribution Agreement referenced below.
News Release FOR IMMEDIATE RELEASE Media Contacts: Investor Contacts: Centocor Centocor Michael Parks Louise MehrotraDistribution Agreement • December 21st, 2007 • Schering Plough Corp • Pharmaceutical preparations
HORSHAM, PA and KENILWORTH, NJ, Dec. 21, 2007 — Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) today announced they have revised their 1998 distribution agreement regarding the development, commercialization and distribution of both REMICADEÒ (infliximab), an anti-tumor necrosis factor (anti-TNF) alpha therapy for chronic inflammatory disorders, and golimumab, Centocor’s next-generation, human, anti-TNF alpha therapy which is currently in Phase 3 trials. Effective upon regulatory approval of golimumab in the EU, the revised agreement will extend the duration of Schering-Plough’s rights to exclusively market REMICADE in its current marketing territories outside the United States beyond 2014 to match the current duration of its exclusive marketing rights for golimumab product. Schering-Plough’s marketing rights to both products will now extend for 15 years after the first golimumab commercial sale.
